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doi:10.1016/j.bbmt.2008.06.014This commentary, sponsored by the National
Marrow Donor Program (NMDP), provides updated
guidelines for unrelated hematopoietic cell donor
selection in the format of frequently asked questions
(FAQ). These revisions to the guidelines, initially pub-
lished in 2003 [1], are based on current and relevant
data that we believe represent optimal donor-recipient
matching criteria.
WHAT IS THE PURPOSE OF THE NMDP DONOR-
RECIPIENT MATCHING CRITERIA?
Since its inception in 1987, the NMDP has
required evaluation of donor-recipient histocompati-
bility matching (HLA-A, -B, and -DR) prior to
unrelated hematopoietic cell transplantation (HCT).
The minimum acceptable match was originally defined
by serologic splits (antigen level of resolution) at these
3 loci (6 possible antigens) and required at least 5
matches, that is, a 5 of 6 match. This requirement
has changed little over the years. Currently, to request
a donor for transplantation, the minimal acceptable level
of matching remains a 5 of 6 match for HLA-A, -B, and
-DRB1. Although only evaluated at antigen level of
resolution for donor release, each of these 3 loci must
be typed at high-resolution by DNA-based methods.
High-resolution typing is defined as the identification
of alleles based on differences in the antigen recogni-
tion site (ARS) domains (Exons 2 and 3 of Class I
and exon 2 of Class II genes). Alleles that are identical
in the ARS domain have not been shown to haveimmunologic differences, and the standard practice
of many transplant centers is to accept these alleles as
a match [2]. In 2005, a requirement for HLA-C typing
was added. The most recent studies have clearly shown
that transplant outcomes can be improved by matching
strategies that increase the overall degree of HLA
compatibility above the minimum (eg, high-resolution
matching, matching for HLA-C, -DP, -DQ, and
haplotypes) [3].
WHAT LITERATURE DISCUSSES THE IMPACT OF HLA ON
HEMATOPOIETIC CELL TRANSPLANTATION OUTCOME?
There are many studies that evaluate the role of
HLA matching in outcome. Our initial recommenda-
tions were based on large, contemporary studies from
3 groups that have evaluated most of the HLA loci
using DNA testing to resolve alleles [4-9]. The num-
ber of pairs evaluated through the NMDP network
has now increased to 3857, and further analysis of
outcome has been published by Lee et al. [10].
OF THE SEVERAL OUTCOME MEASURES, WHICH IS THE
MOST IMPORTANT TO CONSIDER?
The outcome of primary importance is survival.
However, it may be important to consider the effect
of HLA matching on the incidence of acute and
chronic graft-versus-host disease (aGVHD, cGVHD),
treatment-related mortality (TRM), or graft rejection.
Although the impact of HLA matching on survival is
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46 R. A. Bray et al.Table 1. Effect of HLA Mismatching on Survival
Study A B C DRB1
JMDP [4] decrease* (merged A1B) no effect† no effect (merged DR1DQ)
FHCRC [8] no effect no effect decrease no effect
NMDP [9] decrease decrease decrease decrease
NMDP [10] decrease no effect decrease decrease
*‘‘Decrease’’ means a decrease in survival caused by an HLA locus mismatch.
†‘‘No effect’’ means no impact of a mismatch.considered to be the primary determinant for donor
selection, the impact on other outcome measures
may be important in developing a specific risk-adapted
treatment strategy for the recipient.
WHAT DO THE PUBLISHED STUDIES SUGGEST
REGARDING THE ASSOCIATION BETWEEN HLA
MATCHING AND PATIENT OUTCOMES?
Associations between HLA disparity and survival
differ in the studies. The differences are detailed in
Table 1, and are likely the result of differences in study
design as described below.
WHY DO STUDIES GIVE DIFFERENT RESULTS?
Differences in the study designs are summarized in
Table 2. Sample size dictated how the mismatches
were classified across the multiple loci, and different
studies collapsed the loci differently. For example,
Morishima et al [4] combined mismatches at HLA-A
and -B, and at -DR and -DQ, to get a larger sample
size to detect differences among groups. Petersdorf
et al [5-7] collapsed mismatches based on class I versus
class II loci. In the more recent NMDP studies, Flo-
menberg et al [9] and Lee et al [10] looked at each locus
separately. The former analysis employed multivariate
modeling to evaluate mismatches across all loci studied
[9]. The more recent study used ‘‘subset analysis,’’
which means that in examining mismatches at a partic-
ular locus, all other loci were high-resolution matched
[10]. Flomenberg et al [9] found a direct association
between the number of mismatched HLA alleles and
survival, but did not identify a locus-specific effect.
In contrast, Morishima et al and Lee et al identified lo-
cus-specific effects, albeit with somewhat differing re-
sults. Morishima et al identified the combined A/B
group as having a stronger effect on survival than the
other loci. However, because this combined A/B group
included single allelic mismatches for A or B as well as
mismatches for both A and B, the observed effect may
have been magnified by these multiple mismatches.
Lee et al found that a single mismatch either at
HLA-A or HLA-DRB1 had a more profound effect
on survival compared to HLA-B or HLA-C. This
study also found that a high-resolution mismatch had
an effect similar to an antigen level mismatch. The dif-ferences between the findings of Morishima et al and
Lee et al may be explained by the different study
populations. The distribution of alleles in the U.S.
and Japanese populations was quite different, with
little overlap in the alleles and mismatches represented
in the 2 populations. There may be other immunologic
factors that vary among ethnic/racial groups and influ-
ence the relationship between HLA matching and
transplant outcomes. Other patient-related factors
appear to be important, particularly diagnosis and
phase of disease. Both Petersdorf et al [8] and Lee et
al found that the impact of HLA-mismatching was
more pronounced among patients with ‘‘low-risk’’
disease (generally defined as chronic myelogenous leu-
kemia (CML)-chronic phase and/or early-phase mye-
lodysplastic syndromes (MDS) and/or acute leukemia
in first remission). In contrast, for ‘‘high-risk’’ patients,
the increase in overall mortality associated with
advanced disease status appears to obfuscate the bene-
fit of HLA matching.
Taken together, these studies support several gen-
eral concepts in analyzing the effect of HLA mismatch
on survival. First, there appears to be a direct associa-
tion between the number of HLA mismatches and the
risk for mortality. Second, mismatching between
donor and recipient appears to have a greater impact
on patients with ‘‘low-risk’’ disease. Finally, specific
mismatches among the HLA-loci may be tolerated
better within certain ethnic groups.
WHAT DOES THE NMDP SUGGEST AS OPTIMAL MATCH
CRITERIA?
The reports reviewed above show that high-reso-
lution matching for HLA-A, -B, -C, and -DRB1 max-
imizes posttransplant survival (Table 3). Thus,
whenever possible, donors who are high resolution
matched at these 4 HLA loci should be sought. This
does not imply that the unavailability of such a well-
matched donor is a contraindication for transplant. If
a mismatch is unavoidable, a single mismatched donor
(-A, -B, -C, or -DRB1) should be sought. From the
NMDP data reviewed above, it appears that high-res-
olution mismatches have a negative impact similar to
antigen-level mismatches [10]. The sole exception
may occur at HLA-C where high-resolution
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.]mismatches appear to be better tolerated; however,
this particular aspect needs further study. In the
NMDP data, mismatches at HLA-B and -C may be
less detrimental than those at HLA-A and -DRB1,
but this sense is tempered by limited numbers of trans-
plants and by the lack of allele-specific mismatch anal-
yses. That is, within the existing dataset, the
distribution of ‘‘permissive’’ and ‘‘nonpermissive’’ mis-
matches at each locus may be nonuniform. For exam-
ple, more permissive mismatches within the HLA-B
locus mismatched dataset would diminish the negative
impact of mismatching for HLA-B. Clearly, more re-
search is needed in this area.
Of importance is the observation in the NMDP
data that mismatches at HLA-DQ do not show the
same overall negative impact as those at the 4 other
HLA loci [10], but DQ mismatches may be important
in certain disease subsets or when coupled with
mismatches at other loci [3,8]. Similar to HLA-DQ,
mismatches at HLA-DP do not seem to play a role
in overall mortality. In the Lee et al. [10] study,
HLA-DP mismatching was associated with an in-
creased risk for aGVHD; however, there was no
impact on overall survival (OS), and only a suggestion
of an association with increased risk of treatment-
related mortality. In addition, Shaw et al [11] showed
a similar association between HLA-DP mismatches
and an increased risk for aGVHD; however, this
negative impact may be offset by a decreased risk for
disease relapse.
WHAT HLA MATCHING IS REQUIRED FOR STEM CELL
SOURCES OTHER THAN MARROW?
A recent Center for International Blood and
Marrow Transplant Research (CIBMTR) analysis of
unrelated donor transplantation comparing bone
marrow to peripheral blood stem cells (PBSCs) as
hematopoietic cell sources in adults with leukemia
and myelodysplastic syndrome showed a significantly
higher risk of grades II-IV aGVHD and cGVHD fol-
lowing unrelated donor PBSC transplantation with no
survival benefit for PBSC recipients [12]. The data
currently available regarding the role of HLA mis-
match in transplant outcome are generated from series
using bone marrow as a stem cell source. Additional
analyses of transplants using PBSCs as a stem cell
source are needed to determine if the same principles
apply. One alternative stem cell source for cases with-
out a suitable donor is the use of umbilical cord blood.
Recent studies have established the utility of umbilical
cord blood, particularly as a treatment for childhood
leukemia [13]. The impact of HLA matching on out-
comes following unrelated donor umbilical cord blood
transplantation was recently summarized by the
NMDP [14].
48 R. A. Bray et al.WHAT NON-HLA DONOR CHARACTERISTICS SHOULD I
CONSIDER?
Other non-HLA factors are often considered when
selecting donors including CMV negative serology (for
CMV-negative patients), male sex, younger age, ABO
compatibility, larger body weight, and matched race.
In the recent NMDP analysis by Lee et al [10], none
of these factors were important when compared to
HLA matching. This finding contrasted with another
NMDP study by Kollman et al [15], which found
that, in addition to HLA matching, younger donor
age was associated with better survival. In the Kollman
study, there was also no significant association of donor
CMV serology, sex, parity, race, or ABO matching and
recipient survival. Female donors with multiple preg-
nancies were associated with a higher risk of cGVHD,
but there was no impact on survival. Several variables
likely explain the different findings in these 2 studies
including the absolute patient numbers, the definitions
of HLA matching, duration of follow-up, and the con-
sideration of center effects.
HOW DO I SEARCH FOR THE BEST DONOR?
Each search should be initiated based on high-res-
olution HLA assignments of the patient. HLA-A, -B,
-C, and -DRB1 loci should be characterized because
they are important in matching; others assist in design-
ing an efficient search strategy for the patient (Table 3).
The search report received from the NMDP now con-
tains information that indicates the likelihood of each
Table 3. Typing and Matching of Potential Donor and Patient HLA Loci
HLA Locus Search Strategy Matching
Resolution
of Testing
A Yes Recommended High
B Yes Recommended High
C Yes Recommended High
DRA No No
DRB1 Yes Recommended High
DRB3, DRB4,
DRB5
Yes (DRB1
association)*
Unknown†
DQA1 No No
DQB1 Yes (DRB1
association)*
Uncertain‡
DPA1 No No
DPB1 No Uncertain
*Certain alleles at one locus are preferentially associated with some
but not other alleles at a second locus. Knowledge of the patient’s
HLA-DRB3/4/5 or DQB1 assignment provides a check on the
patient’s typing by association, can be used to select the best matched
donor from potential donors equivalently matched at HLA-A, -B,
-C, and -DRB1 and, for DQB1, permits HapLogic match evaluation
and prediction.
†Unknown indicates that the impact of matching has not been
evaluated.
‡Uncertian indicates that studies as to the importance of these loci in
matching. Matching may be necessary if patient possesses anti-HLA
antibodies to the mismatched antigens.potential donor carrying the same alleles as the search-
ing patient. This is especially helpful when faced with
a long list of potential adult or cord blood donors but
only sufficient resources and/or time to type a few
of the potential donors at higher resolution. The
NMDP search algorithm HapLogicSM uses data on
the frequencies of alleles and haplotypes in human
populations to predict the probability of high-resolu-
tion matches at individual HLA loci and at all key
loci simultaneously (Figure 1).
The optimal number of potential donors to select
from the search report should be individualized for
each patient because many factors influence the likeli-
hood of finding a compatible donor. Factors to be con-
sidered include the patient’s alleles and haplotypes (ie,
rare versus common), as well as clinical urgency. For
patients with potential donors with a high probability
of high-resolution matches as determined by HapLo-
gic, high-resolution typing of a small number (eg,
3-5) of donors is usually sufficient. However, more
than 1 donor should be selected because donors may
be unavailable, mistyped, or not matched once high-
resolution testing is complete. For patients with rare
alleles and haplotypes where the likelihood of match-
ing is low, 10 or more donors may be required to
find the best match. In the latter situation, help should
be immediately sought from in-house or NMDP his-
tocompatibility experts to design an effective search
strategy that may include evaluation of worldwide
donor registries. Similarly, for a patient with clinical
urgency, multiple donors should be simultaneously
evaluated and typed.
WHEN SHOULD I LAUNCH AN INTERNATIONAL SEARCH
FOR A DONOR?
The NMDP donor file includes volunteers from
the U.S. as well as Norway, Sweden, Germany, and Is-
rael. The NMDP also provides a general search of
Bone Marrow Donors Worldwide (BMDW) as well
as an automatic detailed search of certain international
registries using the EMDIS (European Marrow Donor
Information System) network that are readily accessi-
ble through NMDP software or by written request.
The BMDW report is particularly helpful to set an
optimal, but realistic, target for the donor search in re-
lation to the number and details of the potential donors
and the time and resources available for a particular
patient. However, the decision on the overall search
strategy and the usefulness of an extended interna-
tional search must also take into account the variation
of allele and haplotype frequencies in different geo-
graphic, racial, or ethnic groups. Whenever deemed
useful, the NMDP can be asked to request search
reports from additional registries and/or with relaxed
matching criteria for difficult cases or specifically
NMDP Matching Guidelines 49Figure 1. Example of an NMDP search report. The columns labeled ‘‘Match Grade/Calculation’’ include a letter indicating the match status of
each allele at the locus indicated (A, allele match; P, potential allele match), the probability of matching both alleles at the locus (100% for the first
donor at each locus), and the probability of a 6/6 HLA-A,-B,-DRB1 allele match (Pr[6] 100% for first donor) and of at most a 5/6 allele match
(Pr[5] 0%).filtered match lists for searches with many donor can-
didates.
HOW LONG DO I SEARCH FOR DONORS?
For patients with common haplotypes, a suitably
matched donor can usually be identified on the first
match run. For patients with uncommon haplotypes,
a well-matched donor may not be readily apparent
on the initial match run. For these patients, we recom-
mend that one request help from a local HLA labora-
tory or NMDP consultant to assist in identifying the
best potential match.
If one is not able to identify an available, acceptably
matched donor within the current NMDP Registry, it
is very unlikely that newly recruited donors will match
the patient in a useful time frame. The NMDP donor
file contains nearly 7 million donors (78% typed for
HLA-A, -B, and -DR) and the NMDP search also pro-
vides a match report of an additional 5 million do-
nors listed in BMDW, so patients who are not able
to find a suitably matched donor in this pool most
likely have haplotypes that are infrequently repre-
sented. The NMDP adds an average of 30,000 new do-
nors to the file monthly. The likelihood that a patient’s
type will be represented in those new recruits when it
did not appear in the initial file of 12 million is
low. Therefore, it is recommended that one reevaluate
the alternative treatment options for those patients anddecide whether to reduce the matching requirements
or select another therapy (eg, unrelated cord blood
transplantation, a partially matched related donor
transplantation, or nontransplant therapy). However,
it should be recognized that search strategies can be
significantly affected by the lack of financial resources.
For some individuals, enlisting the assistance of an
HLA expert can help maximize available resources
by optimizing potential donor screening.
HOW SHOULD THE CLINICAL STATUS OF MY PATIENT
INFLUENCE THE SELECTION OF THE DONOR?
The clinical status of the patient will influence
donor selection. Patients with a relatively stable dis-
ease such as low-risk MDS or a non-SCID primary im-
mune deficiency are less likely to deteriorate quickly,
thus giving their physician time to search and identify
the best matched unrelated donor. In contrast, patients
with acute leukemia may have only a brief remission
time in which transplant is feasible. A prolonged search
time exposes patients to additional toxic chemother-
apy, an increased risk of infection and risk of relapse.
For these patients, a short search time and ongoing
consideration of alternatives (such as using an unre-
lated cord blood unit, a mismatched unrelated donor,
a haploidentical donor, or an investigational therapy)
should be entertained. The risk from the underlying
disease and the availability of therapeutic alternatives
50 R. A. Bray et al.also influences the degree of mismatch considered ac-
ceptable by the physician and patient. Besides consid-
ering differences in life expectancy, the quality of life
associated with transplantation from the best available
unrelated donor should be compared to the quality of
life associated with alternative therapies.
HOW SHOULD POTENTIALLY MATCHED DONORS BE HLA
TYPED?
Donors identified on the NMDP search report
with the highest likelihood of matching the patient
should undergo complete high-resolution testing to
select the best HLA match. DNA-based testing
methods must be used, and a reasonable effort made
to identify the donor’s HLA alleles (Table 3). Some
loci should be characterized because they are key to
matching; others (labeled unknown or uncertain)
should be typed to allow selection of the best match
once other donor characteristics have been taken into
account. An HLA expert might recommend a strategy
that initially targets selected loci for higher resolution
typing to reduce the typing cost; however, this
approach should be balanced against the patient’s
medical condition so as not to unduly delay an urgent
transplant.
DOES THE RACE/ETHNICITY OF THE DONOR NEED TO BE
THE SAME AS THE RACE/ETHNICITY OF THE RECIPIENT?
The direct answer to this question is no. However,
some HLA alleles and haplotypes are distributed at
different frequencies among different racial/ethnic
groups. When searching for a donor, for some alleles,
a high-resolution match is more likely to be found
among persons of the same ethnicity as the patient.
For alleles and haplotypes that are found frequently
in several races/ethnicities, donors from these popula-
tions should be evaluated. HapLogic takes the race/
ethnicity into account when predicting the likelihood
of a high-resolution match. Once high-resolution
matches are identified, the race/ethnicity of the
matched donor should have no significant impact on
the outcome of the transplant. When donor/recipient
pairs matched at the antigen level for HLA-A and -B
and at -DRB1 using DNA-based typing were com-
pared, there was no advantage to being matched by
race [9,10]. It should be recognized that the number
of racially mismatched donor/recipient pairs in these
studies was small, and further studies are needed to
confirm these data.
HOW DO I SELECT THE BEST PARTIALLY MATCHED
UNRELATED DONOR?
Most recently, Lee et al [10] showed that a single
mismatch, antigen-level, or high-resolution, at HLA-
A, -B, -C, or -DRB1 loci was associated with a higher
mortality and decreased survival; however, the reduc-tion in survival may be acceptable in comparison to
the survival rates for currently available alternative
treatments. In the Lee et al. study, mismatches at
HLA-B and/or -C seemed to be better tolerated
than mismatches at HLA-A and -DRB1. The results
were somewhat different in a study by the Interna-
tional Histocompatibility Working Group [16]. Sin-
gle mismatches at the HLA-A locus conferred an
increased risk in transplantations facilitated by the
Japanese Marrow Donor Program (JMDP) but not
in the non-JMDP population analyzed. For the
HLA-C locus, high-resolution mismatching appeared
permissible within the JMDP data but was associated
with increased risk in the non-JMDP transplanta-
tions.
Data from the NMDP and Fred Hutchinson Can-
cer Research Center [8,9] suggest that risks accompa-
nying multiple mismatches may be cumulative or even
synergistic. Although single mismatches at HLA-DP
or -DQ were not associated with increased mortality;
both studies found a small but statistically insignificant
impact on survival when a DQ mismatch occurred in
combination with other mismatches. Therefore,
HLA-DQ matched donors should be favored if other
matching criteria are equal.
For patients who do not appear to have well-
matched donors based on an initial search, more com-
plex strategies are required to identify donors with
specific mismatches. Such strategies are needed to
limit the number of high-resolution mismatches at
other loci. For these searches we recommend that
one request help from a local HLA expert or NMDP
consultant to assist in finding the best mismatch.
It is hoped that in the future it may be possible to
identify ‘‘permissible’’ mismatches; however, currently
there are insufficient data to support this idea as a stan-
dard of practice. For example, in an analysis of NMDP
data, HLA mismatching within a serologic crossreac-
tive group (CREG) was not associated with a survival
benefit in comparison to mismatches outside
a CREG [17]. Likewise, algorithms for selecting less
immunogenic mismatches have not predicted im-
proved outcome [18]. However, a few studies have pro-
vided some information on the potential of permissible
mismatches. Studies published by Morishima et al [19]
on behalf of the International Histocompatibility
Working Group, evaluated specific HLA-A2 allele
mismatched pairs from the JMDP. Morishima’s data
suggested that certain A2 allele-mismatches (*0201
versus *0206) had a higher chance for mortality when
compared to *0201 versus *0205 or *0207. Clearly,
more research is needed to determine if permissive
mismatches exist and how they may be utilized in
donor selection.
In summary, although HLA matching for HLA-
A, -B, -C, and -DRB1 at high resolution is preferred,
the inability to identify a well-matched donor (ie,
NMDP Matching Guidelines 51HLA matched or a single HLA-A, -B, -C, or
-DRB1 mismatch) is not a contraindication for trans-
plantation. For such patients, the physician should
consider the success rate associated with the use of
a mismatched unrelated donor versus the use of other
donor sources (eg, mismatched related donors or un-
related umbilical cord blood donors) or nontransplant
therapies.
SHOULD I BE CONSIDERING PATIENT SENSITIZATION TO
HLA ANTIGENS WHEN SELECTING A HLA MISMATCHED
DONOR?
For patients with antigen or high-resolution mis-
matched donors, an evaluation of presence and speci-
ficity of antibodies directed to HLA antigens may be
important. As a result of blood component support,
many patients will be sensitized to HLA antigens as
demonstrated by the presence of circulating anti-
bodies. Current solid-phase assays make it very easy
to assess the level of presensitization in transplant
recipients. Recent studies in both animals and humans
[20,21] have shown the association of preformed
HLA-directed antibodies on failed engraftment. In
a recent NMDP study [22], approximately one-third
of patients possessed antibodies to HLA antigens.
Among patients with a failed graft, 24% possessed
donor-specific HLA antibodies, compared to 1% in
appropriately matched controls without failed en-
graftment. Interestingly, antibodies against HLA-DP
were quite prominent (60% of antibody positive fail-
ures). This suggests that even though matching for
HLA-DP may not be important for OS, if a patient
has HLA antibodies directed against the mismatched
DP type of the donor, there may be an increased
risk for graft failure. Thus, for patients with HLA an-
tibody and a mismatched allograft, careful antibody
specificity analysis and/or testing of the patient’s
sera for reactivity with cells from potential donors
(ie, crossmatching) may be needed prior to
transplantation.
DOES THE REDUCED INTENSITY OF THE CONDITIONING
PROTOCOL INFLUENCE THE LEVEL OF HLA MATCH THAT I
SELECT?
In a recent retrospective analysis of NMDP data
on outcomes after unrelated donor hematopoietic
cell transplantation following reduced-intensity con-
ditioning (RIC), HLA matching was an important
prognostic factor for survival, suggesting that greater
degrees of mismatch are not more tolerable in the
setting of an RIC transplant regimen [23]. The risk
of using a mismatched donor must be weighed
against the other therapeutic options available to
the patient.IF THE PATIENT HAS A MISMATCHED DONOR, SHOULD I
USE T CELL DEPLETION (TCD)?
TCD reduces the incidence and severity of
aGVHD and increasing donor mismatch increases
risk of GVHD. Despite this, analysis of the NMDP
dataset does not indicate a survival advantage for
TCD, whether a graft is matched or mismatched. A
prospective randomized trial of TCD did not show
improved survival associated with the use of TCD in
either matched or mismatched unrelated donor trans-
plants [24].
SHOULD WE BE CONSIDERING OTHER GENETIC LOCI IN
ADDITION TO HLA FOR DONOR SELECTION?
A recent report suggests that matching for HLA
haplotypes may provide an advantage compared to
merely matching for an HLA phenotype. That is,
matching for 2 HLA haplotypes may be preferred
over matching for 10 of 10 HLA alleles. It is believed
that there are other important transplant-related im-
mune response genes that are carried on chromosome
6. Thus, by matching for an HLA haplotype, it might
be possible to match for these yet to be defined genes.
In a study involving 246 10 of 10 allele matched
unrelated transplants, Petersdorf et al [25], showed
a decreased probability for aGVHD and treatment-
related mortality in patients that were 2 haplotype
matched compared to individuals that were phenotyp-
ically matched. However, the decreased rate of
aGVHD was offset by an increase in relapse, resulting
in an OS that was not different compared to phenotyp-
ically matched individuals. At this time there are insuf-
ficient data to advocate consideration of loci other than
HLA, but NMDP will continue to monitor new devel-
opments in this area.
SHOULD TARGETS OF NATURAL KILLER (NK) CELL
ALLOREACTIVITY BE CONSIDERED?
There are currently no data to unequivocally indi-
cate that unrelated donors with mismatches at HLA
class I loci, that is, the ligands for Killer Immunoglob-
ulin Receptors (KIR), should be preferred in any clin-
ical circumstance. An early report from Ruggeri et al
[26] indicated a strong antileukemic effect and survival
advantage with haploidentical-related donor trans-
plants with particular HLA class I mismatches that
generate donor killer cell reactivity directed toward
patient tissues. This association was observed only
for recipients with AML. A number of subsequent
studies have analyzed the impact of KIR on outcome
with varied conclusions. An analysis of data from the
CIBMTR, European Blood and Marrow Transplant
(EBMT) Registry and the Dutch Registry on the effect
of KIR ligand mismatching on outcomes following
1571 primarily T cell-replete unrelated donor trans-
plantations for myeloid malignancies showed that
52 R. A. Bray et al.KIR ligand incompatibility in either the GVH or
HVG direction had no impact on TRM, treatment
failure, overall mortality, or leukemia recurrence
[27]. In contrast, an analysis of 1770 leukemia patients
who received myeloablative T cell-replete hematopoi-
etic stem cell transplantation (HSCT) from HLA
matched or mismatched unrelated donors showed
that recipient homozygosity for HLA-B or -C epitopes
(ie, potentially missing KIR ligands) may be predictive
for leukemia recurrence following transplantation
from HLA mismatched unrelated donors [28]. A sim-
ilar effect could not be observed following HLA iden-
tical unrelated transplantation. None of the studies
cited here evaluated the donors for the presence or ab-
sence of specific KIR loci required to mediate the pre-
dicted NK reactivity. The influence of donor HLA on
the subsequent reactivity of transplanted NK cells [29]
was also not considered. Finally, the impact of subse-
quent immune suppression on NK recovery may also
affect NK reactivity [30]. At this time more informa-
tion is need to understand the role of this complex
system in outcome.
WHERE CAN I FIND ADDITIONAL INFORMATION?
NMDP Web sites include: http://www.marrow.
org/ and http://bioinformatics.nmdp.org/.
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